High-Impact Research Access to a state-of-the-art synchrotron beamline for confidential macromolecular crystallography positions IMCA-CAT as a premium partner for pharma companies seeking accelerated structure-based drug discovery, presenting a clear opportunity to upsell ongoing access contracts and expanded beamline time.

Ultra-High Throughput Optimized for ultra-high-throughput data acquisition signals strong selling points for CROs and pharma labs with tight project timelines; tailor outreach around scalable data pipelines, rapid turnaround studies, and dedicated support to win multi-year access agreements.

Strategic Partnership Located at Argonne National Laboratory and operated in collaboration with Hauptman-Woodward Institute, IMCA-CAT can leverage co-branding and joint service offerings with established research partners to pursue bundled services, joint marketing, and referral opportunities.

Security & Confidentiality Confidential and proprietary crystallography workflows appeal to pharmaceutical clients with sensitive data; emphasize compliance, data security measures, and private project lanes to differentiate from academic competitors and win enterprise contracts.

Growth Readiness Revenue scale indicates a small, agile specialized facility with room to grow; propose scalable engagement models such as scalable beamtime packages, extended access tiers, and strategic partnerships with larger biotech firms seeking rapid structure-based insights.